• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Shorter interferon course adequately treats melanoma

Article

New York - Treating patients with resected high-risk melanoma with either one month or one year of adjuvant high-dose interferon alpha-2b therapy does not significantly change relapse-free or overall survival, cancerpage.com reports.

New York

- Treating patients with resected high-risk melanoma with either one month or one year of adjuvant high-dose interferon alpha-2b therapy does not significantly change relapse-free or overall survival, cancerpage.com reports.

Researchers prospectively studied 364 patients with stage IIB, IIC or III melanoma, who were randomized within 56 days of curative surgery to receive high-dose intravenous interferon alpha-2b every five to seven days for four weeks with or without a further 48 weeks of treatment, three times per week, according to a study published in the

Journal of Clinical Oncology

.

At 63 months, there was no significant difference between the two groups in relapse-free or overall survival. Median relapse-free survival was 24.1 months in the one-month group and 27.9 months in the one-year group, and median overall survival was 64.4 months and 65.3 months, respectively, according to cancerpage.com.

Patients who received one year of treatment had more grade one to grade two hepatoxicity, nausea/vomiting, alopecia and neurologic toxicity, the team reports.

Related Videos
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 2 - "Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management" - 2 KOLs in this video.
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Heather Woolery-Lloyd, MD, FAAD, an expert on acne
Video 4 - "Navigating Vitiligo Treatment: Decoding Pigmentation & Accessing Care " - 1 KOL in this panel
Video 3 - "Tailored Treatments for Non-Segmental Vitiligo in a 38-Year-Old Male Patient" - 1 KOL in this panel
© 2024 MJH Life Sciences

All rights reserved.